Detecting time-evolving phenotypic components of adverse reactions against BNT162b2 SARS-CoV-2 vaccine via non-negative tensor factorization.

Immunology computational bioinformatics machine learning

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
21 Oct 2022
Historique:
received: 18 02 2022
revised: 05 07 2022
accepted: 22 09 2022
pubmed: 4 10 2022
medline: 4 10 2022
entrez: 3 10 2022
Statut: ppublish

Résumé

Symptoms of adverse reactions to vaccines evolve over time, but traditional studies have focused only on the frequency and intensity of symptoms. Here, we attempt to extract the dynamic changes in vaccine adverse reaction symptoms as a small number of interpretable components by using non-negative tensor factorization. We recruited healthcare workers who received two doses of the BNT162b2 mRNA COVID-19 vaccine at Chiba University Hospital and collected information on adverse reactions using a smartphone/web-based platform. We analyzed the adverse-reaction data after each dose obtained for 1,516 participants who received two doses of vaccine. The non-negative tensor factorization revealed four time-evolving components that represent typical temporal patterns of adverse reactions for both doses. These components were differently associated with background factors and post-vaccine antibody titers. These results demonstrate that complex adverse reactions against vaccines can be explained by a limited number of time-evolving components identified by tensor factorization.

Identifiants

pubmed: 36188188
doi: 10.1016/j.isci.2022.105237
pii: S2589-0042(22)01509-7
pmc: PMC9515008
doi:

Types de publication

Journal Article

Langues

eng

Pagination

105237

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Auteurs

Kei Ikeda (K)

Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Taka-Aki Nakada (TA)

Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Takahiro Kageyama (T)

Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Shigeru Tanaka (S)

Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Naoki Yoshida (N)

Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Tetsuo Ishikawa (T)

Advanced Data Science Project (ADSP), RIKEN Information R&D and Strategy Headquarters, Yokohama, Kanagawa 230-0045, Japan.

Yuki Goshima (Y)

Advanced Data Science Project (ADSP), RIKEN Information R&D and Strategy Headquarters, Yokohama, Kanagawa 230-0045, Japan.

Natsuko Otaki (N)

Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Shingo Iwami (S)

Interdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Aichi 464-8602, Japan.
Institute of Mathematics for Industry, Kyushu University, Fukuoka 819-0395, Japan.
Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Sakyo Ward, Kyoto 606-8501, Japan.
Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Wako, Saitama 351-0198, Japan.
NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Koto Ward, Tokyo 135-8550, Japan.
Science Groove Inc., Fukuoka 810-0041, Japan.

Teppei Shimamura (T)

Division of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.

Toshibumi Taniguchi (T)

Department of Infectious Diseases, Chiba University Hospital, Chiba University, Chiba 260-8670, Japan.

Hidetoshi Igari (H)

Department of Infectious Diseases, Chiba University Hospital, Chiba University, Chiba 260-8670, Japan.
Chiba University Hospital COVID-19 Vaccine Center, Chiba University, Chiba 260-8670, Japan.

Hideki Hanaoka (H)

Clinical Research Centre, Chiba University Hospital, Chiba University, Chiba 260-8670, Japan.

Koutaro Yokote (K)

Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

Koki Tsuyuzaki (K)

Laboratory for Bioinformatics Research, RIKEN Center for Biosystems Dynamics Research, Wako, Saitama 351-0198, Japan.

Hiroshi Nakajima (H)

Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Chiba University Hospital COVID-19 Vaccine Center, Chiba University, Chiba 260-8670, Japan.

Eiryo Kawakami (E)

Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
Advanced Data Science Project (ADSP), RIKEN Information R&D and Strategy Headquarters, Yokohama, Kanagawa 230-0045, Japan.
NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Koto Ward, Tokyo 135-8550, Japan.
Institute for Advanced Academic Research (IAAR), Chiba University, Chiba 260-8670, Japan.

Classifications MeSH